Schizophrenia Research
Volume 117, Issue 1 , Pages 75-82 , March 2010

Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study

  • Lauren C. Bresee

      Affiliations

    • School of Public Health, University of Alberta, Edmonton, Alberta, Canada
    • Institute of Health Economics, Edmonton, Alberta, Canada
    • ,
  • Sumit R. Majumdar

      Affiliations

    • School of Public Health, University of Alberta, Edmonton, Alberta, Canada
    • Institute of Health Economics, Edmonton, Alberta, Canada
    • Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Scott B. Patten

      Affiliations

    • Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
    • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Jeffrey A. Johnson

      Affiliations

    • School of Public Health, University of Alberta, Edmonton, Alberta, Canada
    • Institute of Health Economics, Edmonton, Alberta, Canada
    • Corresponding Author InformationCorresponding author. 2-040 Health Research Innovation Facility, University of Alberta, Edmonton, Alberta, Canada T6G 1K4. Tel.: +1 780 492 7317; fax: +1 780 492 7455.

Received 9 October 2009 ,Revised 9 December 2009 ,Accepted 14 December 2009.

References 

  1. Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes mellitus in Manitoba, 1986–1991. Diabetes Care. 1996;19(8):807–811
  2. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J for the CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr. Res. 2007;90(1–3):162–173
  3. Brown LC, Majumdar SR, Newman SC, Johnson JA. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care. 2005;28(5):1063–1067
  4. Callaghan RC, Boire MD, Lazo RG, McKenzie K, Cohn T. Schizophrenia and incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr. Res. 2009;115(2–3):325–332
  5. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada, 2008. Canadian Journal of Diabetes. 2008;32(Suppl 1):S1–S201
  6. Canadian Psychiatric Association Working Group. Clinical practice guidelines: treatment of schizophrenia. Can. J. Psychiatry. 2005;50(Suppl 1):1S–56S
  7. Chuang HT, Mansell C, Patten SB. Lifestyle characteristics of psychiatric outpatients. Can. J. Psychiatry. 2008;53(4):260–266
  8. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann. Pharmacother. 2003;37(12):1849–1857
  9. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry. 2004;49(11):753–760
  10. Curkendall SM, Mo J, Glasser DB, Stang MR, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J. Clin. Psychiatry. 2004;65(5):715–720
  11. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Moller H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry. 2009;24(6):412–424
  12. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000;26(4):903–912
  13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359
  14. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 2003;23(4):328–335
  15. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can. J. Psychiatry. 2002;47(9):833–843
  16. Hux JE, Ivis F, Flintoff V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512–516
  17. Johnson JA, Vermeulen SU, Hugel G. Background and methods. In: Alberta Diabetes Atlas 2007. Edmonton, Canada: Institute of Health Economics; 2007;p. 1–10
  18. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine. 2008;87(6):329–334
  19. Kisely S, Smith M, Lawrence D, Cox M, Campbell LA, Maaten S. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ. 2007;176(6):779–784
  20. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am. J. Epidemiol. 2006;164(7):672–681
  21. McCreadie RG on behalf of the Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia. Br. J. Psychiatry. 2003;183(6):534–539
  22. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80(1):19–32
  23. Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry. 2008;69(2):316–322
  24. Munk Laursen T, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch. Gen. Psychiatry. 2009;66(7):713–720
  25. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006;86(1–3):15–22
  26. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry. 1991;36(4):239–245
  27. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ. 2007;176(6):S1–S44
  28. Rawson NSB, Malcolm E, D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles. Soc. Psychiatry Psychiatr. Epidemiol. 1997;32(4):191–199
  29. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N. Eng. J. Med. 1998;338(21):1516–1520
  30. Statistics Canada. Census of Population. Available at http://www12.statcan.ca/census-recensement/2006/dp-pd/hlt/97-550/Index.cfm?TPL=P1C&Page=RETR&LANG=Eng&T=1012006;Accessed August 17, 2009
  31. Tu K, Campbell NRC, Chen ZL, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. Open Med. 2007;1(1):18–26
  32. Weber NS, Cowan DN, Millikan AM, Niebuhr DW. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr. Serv. 2009;60(8):1059–1067
  33. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298(22):2654–2664

PII: S0920-9964(09)00607-0

doi: 10.1016/j.schres.2009.12.016

Schizophrenia Research
Volume 117, Issue 1 , Pages 75-82 , March 2010

Article Tools

* Image Usage & Resolution